.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Baxter
Chubb
Mallinckrodt
Federal Trade Commission
Queensland Health
Accenture
Healthtrust
US Army
Boehringer Ingelheim

Generated: June 26, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,083,993

« Back to Dashboard

Claims for Patent: 6,083,993

Title: Method for treating bronchospasm using optically pure R(-) albuterol
Abstract:The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.
Inventor(s): Barberich; Timothy J. (Concord, MA), Young; James W. (Still River, MA)
Assignee: Sepracor Inc. (Marlborough, MA)
Application Number:09/466,107
Patent Claims: 1. A method of treating bronchospasm in a patient with reversible obstructive airway disease, comprising administering to said patient a therapeutically effective amount of optically pure R-(-) albuterol.

2. A method according to claim 1, wherein the albuterol comprises at least 90% by weight of the R(-) isomer and not more than 10% by weight of the S(+) isomer.

3. A method according to claim 1, wherein the albuterol comprises at least 99% by weight of the R(-) isomer and 1% or less by weight of the S(+) isomer.

4. A method according to claim 1, wherein the optically pure R(-) albuterol is administered by inhalation.

5. A method according to claim 4, wherein the optically pure R(-) albuterol is administered in an amount of about 30 .mu.g to about 90 .mu.g.

6. A method according to claim 1, wherein the optically pure R(-) albuterol is administered orally.

7. A method according to claim 6, wherein the optically pure R(-) albuterol is administered in an amount of about 1 mg to about 8 mg.

8. A method according to claim 6, wherein the optically pure R(-) albuterol is administered as a tablet, capsule or syrup.

9. A method according to claim 7, wherein the optically pure R(-) albuterol is administered as a syrup.

10. A method of preventing bronchospasm in a patient with reversible obstructive airway disease, comprising administering to said patient a therapeutically effective amount of optically pure R-(-) albuterol.

11. A method according to claim 10, wherein the albuterol comprises at least 90% by weight of the R(-) isomer and not more than 10% by weight of the S(+) isomer.

12. A method according to claim 10, wherein the albuterol comprises at least 99% by weight of the R(-) isomer and 1% or less by weight of the S(+) isomer.

13. A method according to claim 10, wherein the optically pure R(-) albuterol is administered by inhalation.

14. A method according to claim 13, wherein the optically pure R(-) albuterol is administered in an amount of about 30 .mu.g to about 90 .mu.g.

15. A method according to claim 10, wherein the optically pure R(-) albuterol is administered orally.

16. A method according to claim 15, wherein the optically pure R(-) albuterol is administered in an amount of about 1 mg to about 8 mg.

17. A method according to claim 15, wherein the optically pure R(-) albuterol is administered as a tablet, capsule or syrup.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Express Scripts
UBS
Chubb
Dow
Citi
Moodys
Medtronic
McKinsey
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot